Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145371 | 0.85 | — | — | |
| SCHEMBL7606614 | 0.83 | — | — | |
| SCHEMBL2844037 | 0.81 | — | — | |
| SCHEMBL21603135 | 0.81 | — | — | |
| SCHEMBL13251215 | 0.78 | — | — | |
| SCHEMBL13225638 | 0.76 | CYP2C19 (0.35) | — | |
| SCHEMBL6208224 | 0.76 | — | — | |
| SCHEMBL29372848 | 0.76 | CA2 (0.52) | KDM4EUSP2TSHRCA2ALDH1A1 | |
| SCHEMBL778969 | 0.74 | — | — | |
| SCHEMBL12975722 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094038-A1 | SYNTHESIS | PHOENIX CHEMICALS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| CN-101610994-A | Synthesize two (alkylsulfonyl) ethers from sulfonic acid via the corresponding carboxylic acid sulphonic acid anhydride | PHOENIX CHEMICALS LTD (GB) | 2009-12-23 | — | — | CN | claimed |
| EP-2121587-A1 | SYNTHESIS | Phoenix Chemicals Limited (GB) | 2009-11-25 | — | — | EP | claimed |
| WO-2008084048-A1 | SYNTHESIS | PHOENIX CHEMICALS LIMITED (GB) | 2008-07-17 | — | — | WO | claimed |
| US-20100094038-A1 | SYNTHESIS | PHOENIX CHEMICALS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101610994-A | Synthesize two (alkylsulfonyl) ethers from sulfonic acid via the corresponding carboxylic acid sulphonic acid anhydride | PHOENIX CHEMICALS LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| EP-2121587-A1 | SYNTHESIS | Phoenix Chemicals Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008084048-A1 | SYNTHESIS | PHOENIX CHEMICALS LIMITED (GB) | 2008-07-17 | — | — | WO | disclosed |
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094038-A1 | SYNTHESIS | STS, CA6, CA4 | KDM4E 159/4885CYP3A4 364/4885USP2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.